Johnson & Johnson

Lung cancer
#European Commission #Johnson & Johnson #Lung cancer #Non-small cell lung cancer (NSCLC)

EC approves chemo-free combination for mutated NSCLC 

The European Commission (EC) has extended the approval for Rybrevant (amivantamab), in combination with Lazcluze (lazertinib), to the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC).  It is specifically approved for use in patients with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or exon… Read More

#News #Regulatory

Bladder
#Bladder cancer #Johnson & Johnson #MHRA #Oncology #Phase III trial

MHRA approves erdafitinib for some urothelial carcinomas

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Balversa (erdafitinib) as a monotherapy for the treatment of adults with unresectable or metastatic urothelial carcinoma (UC). Specifically, the indication covers patients harbouring susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations, who have previously received… Read More

#News #Regulatory

Non-small cell lung cancer
#FDA #Johnson & Johnson #Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology

FDA approves combination therapy for non-small lung cancer

The US Food and Drug Administration (FDA) has approved lazertinib (Lazcluze) in combination with amivantamab-vmjw (Rybrevant) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). It is approved in NSCLC with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations,… Read More

#News #Regulatory

Johnson & Johnson head office
#Bispecific therapeutics #GlobalData #Johnson & Johnson #Myeloma #National Institute for Health and Care Excellence (NICE)

J&J will dominate bispecific T-cell engager market

Tecvayli (teclistamab) has been recommended for relapsed and refractory multiple myeloma (RRMM) in England and Wales, leading analysts to predict Johnson & Johnson (J&J) will dominate the bispecific T-cell engagers (BiTEs) market by 2030. The UK National Institute for Health and Care Excellence (NICE) recommended teclistamab… Read More

#News

#Brain disease #Johnson & Johnson #Neurology #Neuroscience

Shaping the future of neuroscience

Berkin Gökbudak, Senior Director of Commercial Strategy for Neuroscience, Pulmonary Hypertension & Cardiovascular & Metabolism, at Johnson & Johnson, looks towards neuroscience strategies that can help advance treatments for brain disorders. The human brain is the last, and greatest, scientific frontier – it’s been described as the most complex structure… Read More

#Exclusive Content

Plaque Psoriasis
#Dermatology #Johnson & Johnson #Phase II trial #Plaque Psoriasis

J&J drug maintains skin clearance in plaque psoriasis for one year

Targeted oral peptide JNJ-2113 maintained skin clearance in moderate-to-severe plaque psoriasis (PsO) through one year in the Phase 2b FRONTIER 2 clinical trial extension, Johnson & Johnson (J&J) has reported. JNJ-2113 is the first and only investigational targeted oral peptide designed to block the IL-23 receptor. Read More

#News

Digital technology concept
#Clarivate #Johnson & Johnson #Roche

Roche and Johnson & Johnson make global innovators list

Roche and Johnson & Johnson are the only pharma companies to feature in Clarivate’s 2024 list of Top 100 Global Innovators, which highlights organisations leading the world in technology research and innovation. This is the first year that Clarivate is ranking, rather than just listing, the top innovators. Johnson &… Read More

#Business & Investment #News

Clinical trial
#Clinical trials #Dermatology #Johnson & Johnson #Plaque Psoriasis

J&J presents successful data from plaque psoriasis trial  

Johnson & Johnson has announced the first data from FRONTIER 2, the long-term extension of the Phase IIb FRONTIER 1 clinical trial evaluating JNJ-2113, the first and only investigational targeted oral peptide designed to block the IL-23 receptor.  IL-23 plays a critical role in pathogenic T-cell activation… Read More

#News

Chemistry
#Cancer research #Click chemistry #Johnson & Johnson #Oncology #Partnership #Shasqi

Partners will use click chemistry to create targeted cancer therapies

Biotech company Shasqi and Johnson & Johnson have entered into a research collaboration to develop new cancer therapies. Shasqi’s Click Activated Protodrugs Against Cancer (CAPAC) platform relies on chemistry for activation of drugs at the tumour. The platform is made up of a tumour-targeting agent and… Read More

#Cancer Research #News

Clinical research
#AACR #Cancer research #Funding #Johnson & Johnson #Lung cancer

AACR START Grant offers industry and academia experience

Postdoctoral and clinical fellows are invited to apply for the AACR-Lung Cancer Initiative at Johnson & Johnson Stimulating Therapeutic Advances through Research Training (START) Grant by June 21, 2023. This three-year, $225,000 grant will provide the opportunity for training and research in both academia and industry,… Read More

#News

#Clinical trials #HIV #Immunology / Virology & Vaccines #Johnson & Johnson

J&J HIV vaccine candidate does not protect women against HIV infection 

An investigational HIV vaccine tested in the “Imbokodo” clinical trial conducted in sub-Saharan Africa did not provide sufficient protection against HIV infection, according to a primary analysis of the study data. It posed no safety concerns. The Phase IIb proof-of-concept study, which began in November 2017, enrolled 2,637 women… Read More

#News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #Johnson & Johnson #Vaccines

Positive new data for J&J Covid vaccine against Delta variant

Johnson & Johnson has announced data that demonstrated its single-shot Covid-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of… Read More

#News #Trending News

#Clinical trials #Covid-19 #Drug delivery #Drug development #Immunology / Virology & Vaccines #Johnson & Johnson #Vaccines

Janssen single-dose COVID-19 vaccine approved for use in the UK

Johnson & Johnson has announced topline efficacy and safety data from the Phase III ENSEMBLE clinical trial, demonstrating that the investigational single-dose Covid-19 vaccine in development at Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468… Read More

#Covid-19 #News #Trending News